introduction/brief CV
The end goal of our research is the development of targeted drug delivery through the detailed investigation of immunology. Specifically, our laboratory's immunological aspects of autoimmune and neuroimmunological disorders are of main interest. We utilize our in-depth understanding of flow cytometry, western blotting, and RT-PCR to analyze various aspects of immunology/immunobiology to identify potential drug targets. To further understand immune and neuroimmune diseases, we utilize models of arthritis, lung inflammation, stress models, experimental autoimmune encephalomyelitis (EAE), and BTBR T+ Itpr3tf/J autistic mouse model in experiments to assess the status of expression of cell surface markers, colony stimulation factors, pro, and anti-inflammatory mediators, cytokines, toll-like receptors (TLRs), chemokines and their receptors, adhesion and costimulatory molecules, and transcription factors pathways. Specifically, we have investigated the effects of an agonist and an antagonist on the histamine four receptor, adenosine A2A receptor, several PARP inhibitors, JAK/STAT inhibitors, peroxisome proliferator-activated receptor-delta (PPARδ) agonist, chemokine receptor antagonist, a STAT3 inhibitor, and a tyrosine kinase inhibitor in different animal diseases models. The results of this work have been published in several peer-reviewed journals. In addition, we have studied the immunological imbalance in autistic children to understand the underlying pathophysiology of this disease and the potential to open new avenues for treatment potentially open new avenues for treatment.
